Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 14/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.64 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575959 | 0.84 | MMP8 (0.63) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| SCHEMBL4575956 | 0.84 | MMP8 (0.63) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL28379254 | 0.83 | MMP8 (0.61) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| SCHEMBL8256427 | 0.82 | HDAC3 (0.68) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| SCHEMBL30711975 | 0.81 | HDAC8 (0.69) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| SCHEMBL15482231 | 0.81 | HDAC3 (0.69) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| SCHEMBL18808354 | 0.81 | CA12 (0.62) | HDAC8HDAC3HDAC2HDAC1MMP8 | |
| SCHEMBL12425759 | 0.80 | HDAC8 (0.90) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| SCHEMBL14244596 | 0.80 | HDAC8 (0.90) | HDAC8HDAC3HDAC2HDAC1HDAC6 | |
| SCHEMBL10077678 | 0.80 | MMP8 (0.71) | HDAC8HDAC3HDAC2HDAC1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2017200966-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | DCB-USA LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20160271276-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2016-09-22 | — | — | US | disclosed |
| US-20160271276-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2016-09-22 | — | — | US | disclosed |
| WO-2015085860-A1 | HETEROCYCLIC HYDROXAMIC ACID COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 广州康缔安生物科技有限公司 | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC8 7/4885HDAC3 3/4885HDAC2 4/4885 |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC8 7/4885HDAC3 3/4885HDAC2 4/4885 |
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC8 7/4885HDAC3 3/4885HDAC2 4/4885 |
| US-20160271276-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC8 7/4885HDAC3 3/4885HDAC2 4/4885 |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC8 7/4885HDAC3 3/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.